DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer.
The names of the study drugs involved in this study are:
* DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein)
* Paclitaxel (a type of antimicrotubule agent)